Research programme: small molecule TYK2 inhibitors - Celgene/Nimbus Therapeutics

Drug Profile

Research programme: small molecule TYK2 inhibitors - Celgene/Nimbus Therapeutics

Alternative Names: NDI 031232; NDI 031301; NDI 031302; NDI 031407

Latest Information Update: 12 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Nimbus Therapeutics
  • Developer Celgene Corporation; Nimbus Therapeutics
  • Class Antineoplastics; Antipsoriatics; Antirheumatics; Small molecules
  • Mechanism of Action TYK2 kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Ankylosing spondylitis; Cancer; Crohn's disease; Multiple sclerosis; Psoriasis; Rheumatoid arthritis; Systemic lupus erythematosus

Most Recent Events

  • 30 May 2018 Preclinical trials in Cancer in USA (PO) (Nimbus Therapeutics pipeline, May 2018)
  • 30 May 2018 Preclinical trials in Crohn's disease in USA (PO) (Nimbus Therapeutics pipeline, May 2018)
  • 30 May 2018 Preclinical trials in Multiple sclerosis in USA (PO) (Nimbus Therapeutics pipeline, May 2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top